» Articles » PMID: 24238690

Adherence to Treatment in Systemic Lupus Erythematosus Patients

Overview
Publisher Elsevier
Specialty Rheumatology
Date 2013 Nov 19
PMID 24238690
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Adherence is defined as "the extent to which a person's behaviour coincides with medical or health advice." Poor adherence to therapeutic regimens is a common and expensive problem in patients with chronic diseases including systemic lupus erythematosus (SLE) and is associated with a higher risk of flares, morbidity, hospitalisations and poor renal outcome. Non-adherence to the treatment is multifactorial for most patients and varies according to unintentional or intentional patterns. The rates of non-adherence in SLE patients range from 3% to 76% depending on the assessment methods, which are all subject to limitations. Indeed, poor adherence to therapeutic regimens is difficult to evaluate. Two studies have shown that undetectable blood hydroxychloroquine (HCQ) concentration may be a simple, objective and reliable marker of non-adherence in SLE patients. The accurate diagnosis of non-adherence may prevent one from incorrectly interpreting disease manifestations as a lack of response. It may then avoid an unnecessary or even dangerous treatment escalation.

Citing Articles

The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study.

Berthelot W, Sirois C, Julien A, Amiable N, Bessette L, Desaulniers P Rheumatol Int. 2025; 45(3):44.

PMID: 39921727 DOI: 10.1007/s00296-025-05804-8.


Medication-related hospitalisations in patients with SLE.

Stanciu M, Lee J, McDonald E, Clark G, Pineau C, Kalache F Lupus Sci Med. 2025; 12(1).

PMID: 39884714 PMC: 11784163. DOI: 10.1136/lupus-2024-001362.


Ten tips in lupus nephritis management.

Teoh S, Yap D, Chan T Clin Kidney J. 2025; 18(1):sfae376.

PMID: 39872638 PMC: 11770280. DOI: 10.1093/ckj/sfae376.


Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS).

Bultink I Lupus Sci Med. 2024; 11(2).

PMID: 39242109 PMC: 11381631. DOI: 10.1136/lupus-2024-001348.


Therapeutic Hydroxychloroquine Blood Levels Are Associated With Fewer Hospitalizations and Possible Reduction of Health Disparities in Lupus.

Garg S, Astor B, Saric C, Valiente G, Kolton L, Chewning B Arthritis Care Res (Hoboken). 2024; 76(12):1606-1616.

PMID: 39187461 PMC: 11605782. DOI: 10.1002/acr.25422.